Optimizing outcomes with azacitidine: Recommendations from Canadian centres of excellence

Current Oncology

Volumn 21, Issue 1, 2014, Pages 44-50

  Wells, R A ^a   Leber, B ^b   Zhu, N Y ^c   Storring, J M ^d  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

5 azacitidine; Clinical outcomes; Guidelines; MDS; Myelodysplastic syndrome; Practical recommendations; Vidaza

Indexed keywords

AZACITIDINE; GRANISETRON; METOCLOPRAMIDE; ONDANSETRON;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLEEDING; CANCER SPECIFIC SURVIVAL; CLINICAL PROTOCOL; DISEASE COURSE; EVIDENCE BASED PRACTICE; HEMATOLOGIC DISEASE; HUMAN; META ANALYSIS (TOPIC); MYELODYSPLASTIC SYNDROME; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT CARE; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SYSTEMATIC REVIEW (TOPIC); THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE;

EID: 84894337699     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.21.1871     Document Type: Article

References (30)

1. Nguyen PL. The myelodysplastic syndromes. Hematol Oncol Clin North Am 2009;23:675-91.
2. Buckstein R, Yee K, Wells RA on behalf of the Canadian Consortium on Evidence-Based Care in MDS. 5-Azacytidine in myelodysplastic syndromes: a clinical practice guideline. Cancer Treat Rev 2011;37:160-7.
3. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88.
4. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012;120:2454-65.
5. Abel GA, Koreth J. Optimal positioning of hematopoietic stem cell transplantation for older patients with myelodysplastic syndromes. Curr Opin Hematol 2013;20:150-6.
6. Koreth J, Pidala J, Perez WS, et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J Clin Oncol 2013;31:2662-70.
7. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Myelodysplastic Syndromes. Ver. 2.2014. [Available online at: http://www.nccn. org/professionals/physician_gls/pdf/mds.pdf (free registration required); cited December 19, 2012]
8. Sekeres MA, Schoonen WM, Kantarjian H, et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst 2008;100:1542-51.
9. Raj K, John A, Ho A, et al. CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia 2007;21:1937-44.
10. Khan R, Schmidt-Mende J, Karimi M, et al. Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells. Exp Hematol 2008;36:149-57.
11. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 2002;20:2429-40.
12. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223-32.
13. Voso MT, Breccia M, Lunghi M, et al. Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. Eur J Haematol 2013;90:345-8.
14. Silverman LR, Fenaux P, Mufti GJ, et al. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer 2011;117:2697-702.
15. Barzi A, Sekeres MA. Myelodysplastic syndromes: a practical approach to diagnosis and treatment. Cleve Clin J Med 2010;77:37-44.
16. Celgene Inc. Vidaza: Azacitidine for Injection, 100 mg Azacitidine per Vial [product monograph]. Mississauga, ON: Celgene Inc.; 2012.
17. Kornblith AB, Herndon JE 2nd, Silverman LR, et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol 2002;20:2441-52.
18. Seymour JF, Fenaux P, Silverman LR, et al. Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol 2010;76:218-27.
19. Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ 2005;173:489-95.
20. Garcia R, De Miguel D, Bargay J, et al. Effectiveness of various dosage regimens of azacitidine in patients with myelodysplastic syndromes: safety and efficacy final data from the Spanish Azacitidine Compassionate Use Registry [abstract 1853]. Blood 2010;116:772.
21. Lyons RM, Cosgriff TM, Modi SS, et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol 2009;27:1850-6.
22. Douvali E, Papoutselis M, Vassilakopoulos TP, et al. Safety and efficacy of 5-azacytidine treatment in myelodysplastic syndrome patients with moderate and mild renal impairment. Leuk Res 2013;37:889-93.
23. Batty GN, Kantarjian H, Issa JP, et al. Feasibility of therapy with hypomethylating agents in patients with renal insufficiency. Clin Lymphoma Myeloma Leuk 2010;10:205-10.
24. van der Helm LH, Alhan C, Wijermans PW, et al. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme. Br J Haematol 2011;155:599-606.
25. Gore SD, Fenaux P, Santini V, et al. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica 2013;98:1067-72.
26. Ruter B, Wijermans PW, Lubbert M. Superiority of prolonged low-dose azanucleoside administration? Results of 5-aza-2′-deoxycytidine retreatment in high-risk myelodysplasia patients. Cancer 2006;106:1744-50.
27. Sloand EM, Yong AS, Ramkissoon S, et al. Granulocyte colony-stimulating factor preferentially stimulates proliferation of monosomy 7 cells bearing the isoform IV receptor. Proc Natl Acad Sci U S A 2006;103:14483-8.
28. Platzbecker U, Aul C, Ehninger G, Giagounidis A. Reduction of 5-azacitidine induced skin reactions in MDS patients with evening primrose oil. Ann Hematol 2010;89:427-8.
29. Kurtin SE, Paterson P, Wintrich S, et al. Patient and family resources for living with myelodysplastic syndromes. Clin J Oncol Nurs 2012;16(suppl):58-64.
30. Santini V, Fenaux P, Mufti GJ, et al. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*. Eur J Haematol 2010;85:130-8.